HK1060514A1 - Thermoformable solid pharmaceutical composition for controlled release of ivabradine. - Google Patents

Thermoformable solid pharmaceutical composition for controlled release of ivabradine.

Info

Publication number
HK1060514A1
HK1060514A1 HK04103476A HK04103476A HK1060514A1 HK 1060514 A1 HK1060514 A1 HK 1060514A1 HK 04103476 A HK04103476 A HK 04103476A HK 04103476 A HK04103476 A HK 04103476A HK 1060514 A1 HK1060514 A1 HK 1060514A1
Authority
HK
Hong Kong
Prior art keywords
ivabradine
pharmaceutical composition
controlled release
solid pharmaceutical
thermoformable
Prior art date
Application number
HK04103476A
Other languages
English (en)
Inventor
Patrick Wuthrich
Herve Rolland
Gilles Briault
Gerard Pichon
Francois Tharrault
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of HK1060514A1 publication Critical patent/HK1060514A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HK04103476A 2000-12-26 2004-05-17 Thermoformable solid pharmaceutical composition for controlled release of ivabradine. HK1060514A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0017015A FR2818552B1 (fr) 2000-12-26 2000-12-26 Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
PCT/FR2001/004134 WO2002051387A1 (fr) 2000-12-26 2001-12-21 Composition pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine

Publications (1)

Publication Number Publication Date
HK1060514A1 true HK1060514A1 (en) 2004-08-13

Family

ID=8858190

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103476A HK1060514A1 (en) 2000-12-26 2004-05-17 Thermoformable solid pharmaceutical composition for controlled release of ivabradine.

Country Status (27)

Country Link
US (1) US20040028743A1 (xx)
EP (1) EP1345594B1 (xx)
JP (2) JP2004518665A (xx)
KR (1) KR100542472B1 (xx)
CN (1) CN1203844C (xx)
AT (1) ATE352290T1 (xx)
AU (1) AU2002228119B2 (xx)
BR (1) BR0116548A (xx)
CA (1) CA2432645A1 (xx)
CY (1) CY1106390T1 (xx)
CZ (1) CZ304587B6 (xx)
DE (1) DE60126332T2 (xx)
DK (1) DK1345594T3 (xx)
EA (1) EA005814B1 (xx)
ES (1) ES2280420T3 (xx)
FR (1) FR2818552B1 (xx)
HK (1) HK1060514A1 (xx)
HU (1) HU229410B1 (xx)
MX (1) MXPA03005840A (xx)
NO (1) NO333776B1 (xx)
NZ (1) NZ526406A (xx)
PL (1) PL203835B1 (xx)
PT (1) PT1345594E (xx)
SI (1) SI1345594T1 (xx)
SK (1) SK286413B6 (xx)
WO (1) WO2002051387A1 (xx)
ZA (1) ZA200304441B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
FR2882556B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
CA2800444C (en) * 2010-06-14 2018-03-20 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
CN101897682B (zh) * 2010-07-13 2012-02-15 石药集团欧意药业有限公司 一种伊伐布雷定或其可药用盐固体制剂及其制备方法
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
EP3082772A1 (en) * 2013-12-20 2016-10-26 Synhton B.V. Pharmaceutical composition comprising amorphous ivabradine
EP3025705B8 (en) 2014-11-25 2018-11-28 Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi Stable ivabradine formulations
CN104398486B (zh) * 2014-12-08 2018-01-12 武汉武药科技有限公司 一种盐酸伊伐布雷定渗透泵控释片及其制备方法
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
KR20190001340A (ko) * 2017-06-27 2019-01-04 에리슨제약(주) 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
DE4138513A1 (de) * 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
WO1997008950A1 (en) * 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
PT998272E (pt) * 1997-08-26 2003-09-30 Aventis Pharma Inc Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
DE19901040A1 (de) * 1999-01-14 2000-07-20 Knoll Ag Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine

Also Published As

Publication number Publication date
MXPA03005840A (es) 2003-09-10
CA2432645A1 (fr) 2002-07-04
CN1203844C (zh) 2005-06-01
KR20030064876A (ko) 2003-08-02
EA200300667A1 (ru) 2003-12-25
AU2002228119B2 (en) 2006-04-27
SI1345594T1 (sl) 2007-04-30
NZ526406A (en) 2005-08-26
PT1345594E (pt) 2007-04-30
NO333776B1 (no) 2013-09-16
DK1345594T3 (da) 2007-05-21
PL203835B1 (pl) 2009-11-30
FR2818552B1 (fr) 2003-02-07
WO2002051387A1 (fr) 2002-07-04
SK9422003A3 (en) 2003-12-02
DE60126332T2 (de) 2007-08-30
ZA200304441B (en) 2004-06-25
KR100542472B1 (ko) 2006-01-11
CN1482901A (zh) 2004-03-17
SK286413B6 (sk) 2008-09-05
WO2002051387A8 (fr) 2004-05-13
CZ304587B6 (cs) 2014-07-23
BR0116548A (pt) 2003-12-23
HUP0302522A3 (en) 2007-09-28
US20040028743A1 (en) 2004-02-12
ATE352290T1 (de) 2007-02-15
EA005814B1 (ru) 2005-06-30
NO20032737D0 (no) 2003-06-16
JP2010100641A (ja) 2010-05-06
NO20032737L (no) 2003-06-16
ES2280420T3 (es) 2007-09-16
PL361662A1 (en) 2004-10-04
FR2818552A1 (fr) 2002-06-28
DE60126332D1 (de) 2007-03-15
HUP0302522A2 (hu) 2003-12-29
EP1345594A1 (fr) 2003-09-24
HU229410B1 (en) 2013-12-30
CY1106390T1 (el) 2011-10-12
JP2004518665A (ja) 2004-06-24
EP1345594B1 (fr) 2007-01-24
CZ20032020A3 (cs) 2003-11-12

Similar Documents

Publication Publication Date Title
HK1060514A1 (en) Thermoformable solid pharmaceutical composition for controlled release of ivabradine.
EA200000584A3 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
EP1187602A4 (en) SUSTAINABLE RELEASE INJECTABLE PHARMACEUTICAL COMPOSITION AND METHODS OF PREPARING THE SAME
EP1120432A4 (en) PROCESS FOR THE PREPARATION OF POLYESTERIC BLOCK COPOLYMERS, COMPOSITIONS BASED ON SUCH COPOLYMERS AND THEIR PREPARATION METHODS
DK1861073T3 (da) Fremgangsmåde til fremstilling af calcium-kompositioner i en kontinuerlig fluid-bed
AU3906701A (en) Permeable composition, controlled release product and methods for the productionthereof
HUP0202880A3 (en) Sustained release compositions, process for producing the same and use thereof
AU2002228119A1 (en) Thermoformable solid pharmaceutical composition for controlled release of ivabradine
IL152243A0 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
NZ526405A (en) Thermoformable solid pharmaceutical composition for the controlled release of perindopril
ZA200110244B (en) Novel xanthone compounds, their preparation and use as medicament.
MXPA01008348A (es) Microcapsulas para la liberacion prolongada de farmacos.
HUP0104787A2 (en) Modification agents for anionic polymerisation and use thereof, as well as the produced polymers and use thereof
AU2002228118A1 (en) Thermoformable solid pharmaceutical composition for controlled release of perindopril
AR032049A1 (es) Una composicion farmaceutica solida termoformable para la liberacion controlada de trimetazidina
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
MXPA02012456A (es) Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y materiales para su sintesis.
PL376537A1 (pl) Kompozycje farmaceutyczne o przedłużonym, kontrolowanym uwalnianiu zawierające naładowane polimery
WO2004100931A3 (en) Use of soaps such as magnesium stearate for increasing the release of drugs
HU9801703D0 (en) Solid pharmaceutical composition having coenzym q10 as active ingredient, process for producing it and its use
EG22658A (en) Matrix tablet enabling prolonged release of gliclazide after administration by the oral route

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181219